Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Y0000821

Molsidomine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine, SIN-10

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H14N4O4
CAS Number:
25717-80-0
Molecular Weight:
242.23
MDL number:
MFCD00869301
UNSPSC Code:
41116107
PubChem Substance ID:
329831170
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

molsidomine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCOC(=O)N=C1O[N-][N+](=C1)N2CCOCC2

InChI

1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3/b10-8-

InChI key

XLFWDASMENKTKL-NTMALXAHSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Molsidomine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
E Böhme et al.
European heart journal, 4 Suppl C, 19-24 (1983-05-01)
[Treatment of myocardial ischemia with molsidomine].
J Dirschinger et al.
Medizinische Klinik (Munich, Germany : 1983), 85(3), 141-144 (1990-03-15)
[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?].
V Schächinger et al.
Der Internist, 38(5), 438-447 (1997-05-01)
R E Nitz et al.
Pharmacotherapy, 7(1), 28-37 (1987-01-01)
The long-acting antianginal drug molsidomine has been shown experimentally to reduce myocardial infarct size when administered prior to or after cardiac insult. This is due to several drug actions. Dilation of postcapillary capacitance vessels diminishes venous return, preload, heart dimensions
[Pharmacology of molsidomine and its active metabolites].
E Böhme
Medizinische Klinik (Munich, Germany : 1983), 85 Suppl 1, 7-10 (1990-02-01)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service